Results 231 to 240 of about 317,261 (329)

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Altered X-chromosome inactivation of the TLR7/8 locus and heterogeneity of pDCs in systemic sclerosis. [PDF]

J Exp Med
Du Y, Faz-Lopez B, Ah Kioon MD, Cenac C, Pierides M, Lakin KS, Spiera RF, Chaumeil J, Truchetet ME, Gordon JK, Guéry JC, Barrat FJ.   +11 more
europepmc   +1 more source

Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin‐degrading enzyme, a new molecular vulnerability in multiple myeloma

British Journal of Pharmacology, EarlyView.
Inhibitors of insulin‐degrading enzyme boost PI cytotoxicity through an increased sensitivity of proteasome to PI inhibitors, induction of ISR, DNA damage and Myc down‐regulation. They overcome PI resistance in vitro and induce tumour regression in vivo.
Laetitia Lesire, Rebecca Deprez‐Poulain, Damien Bosc, Florence Leroux, Valerie Landry, Sarah Ourabah, Morgane Tardy, Clara Maillard, Ronan Gealageas, Julie Dumont, Adrien Herledan, Sandrine Warenghem, Manon Cruette, Celine Lenglart, Alexandre Biela, Catherine Piveteau, Eva De Smedt, Catharina Muylaert, Wenguang Liang, Elvira Garcia De Paco, Elina Alaterre, Sara Ovejero, Nicolas Robert, Fabien Delahaye, Wei‐Jen Tang, Peter van Endert, Elke De Bruyne, Jérôme Moreaux, Benoit Deprez   +28 more
wiley   +1 more source

Gene reactivation upon erosion of X chromosome inactivation in female hiPSCs is predictable yet variable and persists through differentiation. [PDF]

Stem Cell Reports
Raposo AC, Caldas P, Jeremias J, Arez M, Cazaux Mateus F, Barbosa P, Sousa-Luís R, Água F, Oxley D, Mupo A, Eckersley-Maslin M, Casanova M, Grosso AR, da Rocha ST.   +13 more
europepmc   +1 more source

An evolutionarily conserved early replicatig segment on the sex chromosomes of man and great apes [PDF]

, 1986
Schempp, Werner, Weber, Bernhard, Wiesner, Henning   +2 more
core  

Molecular and Cell Biological Characterization of Patient‐Derived Head and Neck Squamous Carcinoma Cell Lines

Cancer Science, EarlyView.
Patient‐derived head and neck squamous cell carcinoma (HNSCC) cells were genomically and cytogenetically characterized, revealing actionable alterations and chromosomal instability. Targeted therapies suppressed growth according to EGFR amplification or PIK3CA mutation status.
Kazue Ito, Noriko Ishida, Shin Ito, Norihisa Shindo, Satoshi Souma, Mai Mochizuki, Haruna Fujimori, Keiichi Tamai, Takayuki Imai, Tomoko Yamazaki, Kazunori Yamaguchi, Kento Sasaki, Yuya Miyakura, Shigekazu Murakami, Yuka Unno, Naoki Asano, Yukinori Asada, Jun Yasuda   +17 more
wiley   +1 more source

The role of genetic testing in accurate diagnosis of X-linked sideroblastic anemia: novel ALAS2 mutations and the impact of X-chromosome inactivation. [PDF]

Sci Rep
Jové-Solavera D, Rámila M, Ferrer-Cortés X, Olivella M, Venturi V, Morado M, Hernández-Rodríguez I, Khan A, Pérez-Montero S, Tornador C, Germing U, Gattermann N, Sanchez M.   +12 more
europepmc   +1 more source

RNF12 is an X-Encoded dose-dependent activator of X chromosome inactivation.

Cell, 2009
I. Jonkers, T. S. Barakat, Eskeatnaf Mulugeta Achame, Kim Monkhorst, A. Kenter, E. Rentmeester, F. Grosveld, J. Grootegoed, J. Gribnau   +8 more
semanticscholar   +1 more source

Nonrandom X Chromosome Inactivation [PDF]

, 2020
openaire   +1 more source